NuScale Power shares have slid roughly 70% over the past year, trading around $9.70 after hitting a 52-week high near $57.42. The sharp drawdown has improved the stock’s appeal to some investors on valuation grounds, but the company’s path to commercial revenue and binding contracts remains incomplete—keeping the name in a high-speculation category.
Key takeaways
- Price move: NuScale Power shares are down about 70% over the past year and trade around $9.70, far from the 52-week high near $57.42.
- Catalyst focus: Investors are watching whether ENTRA1 Energy and the Tennessee Valley Authority (TVA) can move from discussions to a definitive power purchase agreement related to up to 6 gigawatts of NuScale reactors.
- Financial backdrop: NuScale reported about $1.9 billion in cash, cash equivalents, and investments as of June, providing a liquidity cushion.
- Key implication: With limited commercial revenue so far, the equity’s risk profile is still tied to contract timing and project execution rather than near-term earnings power.
What drove the sharp decline
The stock’s persistent weakness reflects the gap between progress on nuclear technology and the slower, contract-driven nature of commercialization. The company’s 77-megawatt small modular reactor design received approval from the Nuclear Regulatory Commission in 2025, and NuScale has built a supply chain with more than 60 specialized partners. Those milestones are important for credibility and execution capacity.
However, the commercial story depends on binding customer commitments. Data cited in the article points to a commercialization partner, ENTRA1 Energy, working with TVA on a potential deployment of up to 6 gigawatts, which could involve 72 NuScale modules. But as of the reporting, ENTRA1 and TVA have not signed a definitive power purchase agreement, and NuScale has not yet generated meaningful commercial revenue.
Quarterly figures included in the article underscore that point: revenue in the second quarter was about $75,000. With sales still minimal, the equity tends to trade on forward-looking probability—making it sensitive to contract headlines, regulatory developments, and any change in perceived execution risk.
Market reaction: balance-sheet support, but dilution risk
Alongside the commercialization uncertainty, investors have been weighing whether NuScale has enough funding runway without relying too heavily on additional capital raises. The article highlights that NuScale ended June with approximately $1.9 billion in cash, cash equivalents, and investments. For a company still in early stages of revenue generation, that amount can reduce immediate financing stress.
At the same time, the report points to dilution already in motion. During the first six months of 2026, NuScale sold nearly 89.7 million shares through an at-the-market offering, raising about $985 million after expenses. That is supportive in the near term, but it also signals that equity funding has been part of the capital plan—an important consideration for shareholders.
With the stock around $9.70, the article estimates a market capitalization around $4 billion. That valuation remains difficult for conservative investors to justify given the lack of binding orders for the first major commercial project and the absence of substantial revenue to date.
Why some investors are watching the stock near $7
The article’s central valuation argument is that a move toward $7 per share could improve the risk-reward profile. At that level, the stock would still be below current trading, roughly 28% under the referenced price and slightly under the current 52-week low of $7.21. The appeal at $7 is not framed as the stock becoming “cheap,” but rather as offering a larger margin of safety while retaining meaningful upside if the TVA project advances.
Crucially, the article ties the potential willingness to buy above or below that threshold to whether key contract milestones become binding. Specifically, it suggests that if ENTRA1 signs a binding agreement with TVA and NuScale gains a clearer path to deploying dozens of reactors, the risk profile would change—making higher prices more defensible.
Conversely, the piece indicates stronger interest at levels below $6, reflecting the idea that further downside could increase the probability-weighted return while the company remains dependent on future orders and financing discipline.
Bigger picture for nuclear commercialization
NuScale’s situation illustrates a broader investor challenge in advanced energy and infrastructure: technology milestones can arrive faster than commercialization milestones. Reactor approvals and partner ecosystems matter, but large-scale deployment typically hinges on long-term off-take arrangements and project-level economics.
For investors, the key swing factor is whether potential deployments move from prospective discussions to contracted commitments. In this case, the reported linkage to TVA and an up-to-6-gigawatt program keeps attention on the timing and certainty of power purchase agreements, rather than on quarterly earnings momentum.
Funding remains another key variable. While the reported cash balance provides room to operate, recent at-the-market issuance described in the article reminds shareholders that capital needs can persist as projects advance from development toward construction.
Looking ahead, investors will likely focus on any progress toward a definitive TVA power purchase agreement, additional updates on commercialization partner ENTRA1, and future financial disclosures that clarify burn rate and funding plans. In the near term, the market will continue to price NuScale more like a contract-driven developer than a revenue-generating utility—until binding orders and sustained commercial revenue become reality.
